NCT07715669RecruitingEarly phase 1
Antidepressant Therapy for Improved Blood Vessel Health After Preeclampsia
Role of Antidepressant Therapy to Improve Vascular Function After Preeclampsia
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
Preeclampsia is a condition in pregnancy where a woman develops high blood pressure and other complications. Women who develop preeclampsia are 4 times more likely to have heart disease later in life. They are also more likely to have depression after pregnancy. Why they are more likely to develop these conditions is not known. It may be because their blood vessels were damaged during pregnancy. Changes in blood vessel health can predict heart disease. These changes have been recorded after pregnancy in women who had preeclampsia. These changes have also been recorded in women who have depression. In the previous phase of this award, we found that women who had preeclampsia in pregnancy had changes in blood vessel health after pregnancy. We also found that if these women were taking a medicine to treat depression, their blood vessel health was normal. This could mean that treatment for depression can also increase blood vessel health in women who had preeclampsia. In this project we will study how changes in blood vessel health are related to preeclampsia and depression in women who have had both. We will also study how medicine to treat depression can improve blood vessel health after preeclampsia. We will do this by measuring how blood vessels work in women who have had preeclampsia compared to women who did not, and in women who have depression and women who do not. This will tell us more about why risk for depression and heart disease is higher in women who have had preeclampsia. It will also help us understand if medicine for depression can reduce cardiovascular disease risk after preeclampsia.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 15 Jul 2026
- Start date
- 11 Aug 2026
- Primary completion date
- Mar 2027
- Lead sponsor
- Anna Stanhewicz, PhD
- NCT number
- NCT07715669
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 40
- From 11 Aug 2026 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- current antihypertensive or cholesterol-lowering medication
- currently using SSRI medications
Other illness
- history of cardiovascular, metabolic, and/or skin diseases
- current or history of tobacco/nicotine/ e-cigarette use
- history of gestational diabetes
- allergy to materials used during the experiment (e.g. latex),
- known allergy to study drugs
Other
- currently pregnant
Who the study is looking for
- 18-24 years old,
- 12 weeks - 5 years post pregnancy
- one of the following:
- history of a normal pregnancy with a current diagnosis of depression,
- history of a normal pregnancy without a current diagnosis of depression,
- history of a preeclamptic pregnancy with a current diagnosis of depression
- history of preeclamptic pregnancy without a current diagnosis of depression.
Age in the registry: 18 years to 45 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Iowa Coordinator of this site? Confirm its status | Iowa City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.